

Press Release

23 January 2023 20:50:00 CET

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)

January 23 2023

The shareholders of 2cureX AB (publ), org. no. 559128-0077, are hereby invited to an extraordinary general meeting. The extraordinary general meeting will be held at 10:00 (CET) on February 10 2023 at the premises of PwC, located at Anna Lindhs Plats 4 in Malmö.

Notification of participation etc.

Shareholders who wish to attend the extraordinary general meeting must:

- be recorded as shareholders in the share register maintained by Euroclear Sweden AB on February 2 2023, and;
- no later than on February 6 2023 have given written notice of their participation by mail to 2cureX AB, c/o Talenom Consulting AB, Lilla Strandgatan, 261 22 Landskrona. Notice can also be done by email to ir@2curex.com. The notification should state name, personal identification number or registration number, address, daytime phone number and when applicable information regarding any representative, proxy and or at most two assistants. If applicable, the notification must include authorization documents such as a certificate of registration or equivalent documents.

Nominee-registered shares

In order to be entitled to participate at the meeting, shareholders who has his or her shares registered in the name of a trustee must, through the care of the trustee, have the shares registered in his or her own name, so that he or she is registered in the share register maintained by Euroclear Sweden AB as of the record date on February 2nd, 2023. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register the shares in their own name must, in accordance with the respective trustee's routines, request that the trustee make such voting rights registration. Voting rights registration that has been requested by shareholders in such time that the registration has been made by the relevant trustee no later than February 6th, 2023, will be taken into account in the preparation of the share register.

Proxy

Shareholders represented by proxy shall issue a written and dated power of attorney signed by the shareholder. A power of attorney issued by a legal entity shall have a registration certificate attached, or if such certificate does not exist, equivalent documents. The original power of attorney and any registration certificate should, in advance of the general meeting be sent to the Company at the address above.

Number of shares and votes

The number of outstanding shares and votes in the company at the time of this notice amounts to 17 602 916 shares and 17 602 916 votes. The company holds no own shares.

Proposed agenda

1. Appointment of a chairman of the general meeting
2. Preparation and approval of the voting register
3. Approval of the agenda
4. Appointment of one (1) or two (2) persons to verify the minutes of the meeting
5. Determination of whether the extraordinary general meeting was duly convened
6. Appointment of Board of directors
7. Closure of the general meeting

Appointment of a chairman of the general meeting (item 1)

The Board proposes that Bjarke Sanbeck is appointed as chairman of the extraordinary general meeting.

Appointment of Board of directors (item 6)

The Board of directors proposes that the extraordinary general meeting resolves for the Board of directors to consist of current members Povl-André Bendz, Camilla Huse Bondesson, Michael Schaefer, Ole Thastrup and new member Michel Klimkeit. With this the Board of directors shall consist of 5 board members. It is proposed that Povl-André Bendz is re-elected as Chairman of the Board.

This proposal stems from a process of continuous assessment and streamlining by the Board of directors of its required competences, considering the current stage of the company and its foreseeable development. From this perspective, the proposed new member, Michael Klimkeit, would strengthen the financial competence of the Board with his close knowledge of the international investor environment, including institutional investors.

Michel Klimkeit trained as an economist and later completed an MBA in Hamburg and Rotterdam. He started his professional career at an asset management firm, followed by a stint at a German based Fintech. Starting in 2016, he managed a European small and midcap equity strategy at Warburg Invest, a German institutional asset manager. At the beginning of 2020 he joined Auretas Family Trust, a multifamily office where he manages the companies' private markets and private equity strategies. He has over 12 years of professional experience in capital markets and a keen academic interest in corporate strategy and development, as well as extensive experience with healthcare companies, both as an investor and strategic advisor.

Personal data

Personal data retrieved from the share register maintained by Euroclear Sweden AB, notification of participation at the meeting and information about deputies, proxies and assistants will be used for registration, preparation of the voting list for the meeting and, where applicable, minutes of the meeting.

Other

The notice and proxy forms will be made available at the premises of the Company, 2cureX, Fruebjergvej 3, 2100 Copenhagen, Denmark and on the Company's website (www.2curex.com) and will be sent to the shareholders who request it and state their postal address.

Shareholders are informed of their right under Chapter 7, Section 32 of the Swedish Companies Act to request information from the Board of directors and the CEO.

Malmö in January 2023

2cureX AB (publ)

The Board of directors

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in 2cureX AB, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

[NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB \(PUBL\)](#)